Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

126P - Chemotherapy and stereotactic ablative radiotherapy in newly diagnosed and recurrent locally advanced non-small cell lung cancer patients unfit for concurrent radio-chemotherapy: Sub-analysis and update of START-NEW-ERA non-randomised phase II trial


31 Mar 2023


Poster Display session


Fabio Arcidiacono


Journal of Thoracic Oncology (2023) 18 (4S): S106-S115.


F. Arcidiacono1, P. Anselmo2, M. Casale3, C. Zannori3, F. Loreti3, M. Italiani3, B. Enrico3, S. Fabiani3, G. Marchetti3, V. Tassi3, F.A. Mancioli3, M. Muti3, A. Guida3, S. Bracarda3, M. Ragusa3, E. Maranzano3, F. Trippa3

Author affiliations

  • 1 Terni/IT
  • 2 "S.Maria" Hospital, 05100 - Terni/IT
  • 3 "S.Maria" Hospital, Terni/IT


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 126P


Early analysis1 of a single arm phase II trial assessed local control (LC) and safety of SAbR in unresectable LA-NSCLC patients unfit for concurrent chemo-radiotherapy (ChT-RT). Here we report outcomes of LA-NSCLC patients submitted to ChT and SAbR.


Between December 31, 2015 and June 30, 2022 71 LA-NSCLC patients were enrolled. 40 (56%) and 31 (44%) received neoadjuvant ChT+SAbR and SAbR, respectively. Among patients receiving ChT, 15 (37%) received Durvalumab. The tumor volume included primary tumor (T) and any regionally positive node/s (N). The co-primary study endpoints were LC and safety.


The median age was 71 years (range, 52–85). 36 (90%) and 4 (10%) patients had PS 0–1 and 2, respectively. Histology was squamous cell carcinoma (SCC) and adenocarcinoma (ADC) in 52% and 48%, respectively. The stage was IIB, IIIA, IIIB and IIIC in 4 (10%),13 (33%), 17 (42%) and 6 (15%) patients, respectively. Median prescribed dose was 45 Gy (range, 35–55) and 40 Gy (35–45) in 5 daily fractions to T and N, respectively. After a median follow-up of 26 months (range, 6–66), 14 (35%) patients had experienced local recurrence (LR). The median LR-free survival (FS) was not reached (95% CI, 28 to not reached). The 1-, 2- and 4- year LR-FS rates were 86 ± 6%, 67 ± 8% and 50 ± 10%, respectively. At last follow-up, 23 (58%) patients were alive. Median overall survival (OS) was 50 months (95% CI, 31–55). The 1, 2, and 4-year OS rates were 92 ± 5%, 70 ± 8% and 51 ± 9%, respectively. 14 (35%) patients developed distant progression (dP). The median dP-FS was not reached (95% CI, 16 to not reached). The 1, 2, and 4-year dP-FS rates were 86 ± 6%, 56 ± 9% and 56 ± 9%, respectively. 2 (5%) patients developed grade (G) ≥3 esophageal and lung toxicity.


LA-NSCLC patients treated with ChT and SAbR had optimal LC and promising OS with low rate of G3 toxicity. Our early outcomes would suggest the feasibility of using this approach in LA-NSCLC patients unfit for concurrent ChT-RT.

1 Int J Radiat Oncol Biol Phys 2022; S0360-3016(22)03459-9. doi: 10.1016/j.ijrobp.2022.10.025.

Clinical trial identification


Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.